TD Asset Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

TD Asset Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-95,435	Closed	-$1.68M	–	1582
2021 Q3	$1.68M	Sell	95,435 -214,820	-69%	-$2.51M	﹤0.01%	1134
2021 Q2	$2.03M	Sell	310,255 -1,424	-0.5%	-$13.4K	﹤0.01%	1089
2021 Q1	$3.34M	Buy	311,679 +17,520	+6%	+$217K	﹤0.01%	943
2020 Q4	$4.33M	Buy	294,159 +52,792	+22%	+$761K	0.01%	829
2020 Q3	$3.42M	Buy	241,367 +164,792	+215%	+$1.64M	﹤0.01%	806
2020 Q2	$617K	Buy	+76,575	New	+$474K	﹤0.01%	1175

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

TD Asset Management's TRIL Position: Q4 2021 in Review

TD Asset Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 95,435 shares — an estimated $1.68M sold.

TD Asset Management first reported a position in TRIL in Q2 2020 and held it in 6 quarters. The position peaked at $4.33M in Q4 2020. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

TD Asset Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
TD Asset Management sold 95,435 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $1.68M.
TD Asset Management first reported a position in Trillium Therapeutics Inc. in Q2 2020 and held it in 6 quarters.
TD Asset Management's Trillium Therapeutics Inc. position peaked at $4.33M in Q4 2020.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on TD Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.